DTREF
DATELINE RESOURCES LTD$0.0548 −0.01 (−13.02%)
Oct 27 4:00 PM ET · prev $0.0630
1 year
−70.0%
from $0.1825 · Oct 28
30 days
−27.0%
from $0.0751
52-week range
$0.0486–0.3784
−86% from high · low Sep 24
Avg volume 20D
2.88M
shares / day
Short interest
3.70M
−64.9%
Days to cover
1.0
at average volume
Price
Daily candles with volume. Pins mark insider trades, rating changes, 13F stakes, reports, catalysts and short-interest jumps.
No data for this timeframe.
- X Jul 31 Short interest falls 34.5% to 1.03M
- X Aug 14 Short interest jumps 675.8% to 7.96M
- X Aug 31 Short interest falls 91.2% to 697.5K
- X Sep 15 Short interest jumps 100.7% to 1.40M
- X Sep 30 Short interest jumps 652.8% to 10.54M
- X Oct 15 Short interest falls 64.9% to 3.70M
Signal stack
Where each data set points today.
- Short sellersCOVERING
Short interest −64.9% to 3.70M shares. 1.0 days to cover.
- TrendDOWNTREND
14% below its 50-day average.
- SocialQUIET
No Reddit mentions this week. Last mention Sep 28.
Reddit
Recent posts
Rare Earths High Flyer up 55% Today/DTREF
1 upvotes · 0 comments
Rare Earth’s High Flyer Up 60% today/DTREF
1 upvotes · 5 comments
Earnings setup
Estimates| Period | EPS est. | Range | 30D rev. | Revenue |
|---|---|---|---|---|
| Current Q | — | — | — | $0.00 |
| Next Q | — | — | — | $0.00 |
| Current FY | — | — | — | $0.00 |
| Next FY | — | — | — | $0.00 |
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
Recent
Jul 28, 2026
Drug approval
EMA: Human medicines European public assessment report (EPAR): Itvisma, onasemnogene abeparvovec, Date of authorisation: 30/06/2026, Status: Authorised
Human medicines European public assessment report (EPAR): Itvisma, onasemnogene abeparvovec, Date of authorisation: 30/06/2026, Status: Authorised
Short side
FINRA· Oct 15, 20263,700,921
shares short
-64.9%
vs prior settlement
1.0
days to cover
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Jul 28, 2026 Drug approval
EMA: Human medicines European public assessment report (EPAR): Itvisma, onasemnogene abeparvovec, Date of authorisation: 30/06/2026, Status: Authorised
Human medicines European public assessment report (EPAR): Itvisma, onasemnogene abeparvovec, Date of